Relapsed or Refractory Multiple Myeloma
Showing 1 - 25 of 45
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for
Completed
- Relapsed or Refractory Non-Hodgkin's Lymphoma
- Relapsed or Refractory Multiple Myeloma
- BEBT-908 for injection
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Oct 9, 2023
Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Forimtamig
- +2 more
- (no location specified)
Sep 20, 2023
Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Cevostamab
- +2 more
- (no location specified)
Jun 22, 2023
Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)
Recruiting
- Relapsed or Refractory Multiple Myeloma
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 24, 2023
Relapsed or Refractory Multiple Myeloma Trial in Canada, United States (mRNA-2736)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- mRNA-2736
-
Birmingham, Alabama
- +12 more
Jun 15, 2023
Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- YTS104 Cells injection
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 13, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (JNJ-79635322)
Recruiting
- Relapsed or Refractory Multiple Myeloma
-
Edegem, Belgium
- +16 more
Jan 27, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (CC-92480, Carfilzomib, Dexamethasone)
Recruiting
- Relapsed or Refractory Multiple Myeloma
- CC-92480
- +2 more
-
Mobile, Alabama
- +130 more
Jan 27, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Teclistamab, Pomalidomide, Bortezomib)
Recruiting
- Relapsed or Refractory Multiple Myeloma
- Teclistamab
- +4 more
-
Berkeley, California
- +188 more
Jan 27, 2023
Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)
Withdrawn
- Relapsed or Refractory Multiple Myeloma
- (no location specified)
Jan 26, 2023
Relapsed or Refractory Multiple Myeloma Trial in Beijing, Guangzhou, Hangzhou (STI-6129)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- STI-6129
-
Beijing, Beijing, China
- +3 more
Jan 9, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Carfilzomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Relapsed or Refractory Multiple Myeloma
- Carfilzomib
- +2 more
-
Fountain Valley, California
- +107 more
Dec 7, 2022
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Pomalidomide)
Active, not recruiting
- Relapsed or Refractory Multiple Myeloma
- Carfilzomib
- +2 more
-
Birmingham, Alabama
- +45 more
Dec 6, 2022
Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))
Recruiting
- Relapsed or Refractory Multiple Myeloma
- SVd (Selinexor+Bortezomib+dexamethasone)
- Vd (Bortezomib+dexamethasone)
-
Hefei, Anhui, China
- +33 more
Aug 14, 2022
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Daratumumab, Pomalidomide)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Talquetamab
- +3 more
-
Tucson, Arizona
- +191 more
Aug 11, 2022
Relapsed or Refractory Multiple Myeloma Trial in Nagoya, Shibuya-ku (Elranatamab (PF-06863135))
Active, not recruiting
- Relapsed or Refractory Multiple Myeloma
- Elranatamab (PF-06863135)
-
Nagoya, Aichi, Japan
- +1 more
Jun 20, 2022
Relapsed or Refractory Multiple Myeloma Trial in Germany, Spain, United States (INCB001158, Daratumumab SC)
Completed
- Relapsed or Refractory Multiple Myeloma
- INCB001158
- Daratumumab SC
-
Daphne, Alabama
- +28 more
May 5, 2022
Relapsed or Refractory Multiple Myeloma Trial in Australia, China (EMB-06)
Recruiting
- Relapsed or Refractory Multiple Myeloma
- EMB-06
-
Buderim, Queensland, Australia
- +5 more
May 4, 2022
Relapsed or Refractory Multiple Myeloma Trial in United States (CAR2 Anti-CD38 A2 CAR-T Cells)
Completed
- Relapsed or Refractory Multiple Myeloma
- CAR2 Anti-CD38 A2 CAR-T Cells
-
Jacksonville, Florida
- +3 more
Mar 14, 2022
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia Trial in Worldwide (AMG 176, Azacitidine,
Recruiting
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Acute Myeloid Leukemia
- AMG 176
- +2 more
-
Duarte, California
- +23 more
Feb 9, 2022
Relapsed or Refractory Multiple Myeloma Trial in West Hollywood, Rochester (ORIC-533)
Recruiting
- Relapsed or Refractory Multiple Myeloma
-
West Hollywood, California
- +1 more
Feb 2, 2022
Relapsed or Refractory Multiple Myeloma Trial in Beijing (Mitoxantrone Hydrochloride Liposome injection, Bortezomib for
Recruiting
- Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome injection
- +2 more
-
Beijing, Beijing, ChinaBeijing Chaoyang Hospital, Capital Medical University
Jan 16, 2022